Tg Therapeutics (TGTX) Net Cash Flow Growth (1y) (2013 - 2026)
Tg Therapeutics (TGTX) Net Cash Flow Growth (1y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 172.72% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 53.21% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.60% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,421.76% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 149.49% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -100.75% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -104.22% |
| 10 | Tg Therapeutics | 7.46 Bn | 6.78 Bn | 199.14 Mn | 1,446.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1,446.38% |
| Mar 31, 2026 | 860.34% |
| Dec 31, 2025 | 131.90% |
| Sep 30, 2025 | -148.74% |
| Jun 30, 2025 | -140.33% |
| Mar 31, 2025 | -173.61% |
| Dec 31, 2024 | 72.53% |
| Sep 30, 2024 | 109.51% |
| Jun 30, 2024 | -79.08% |
| Mar 31, 2024 | 57.26% |
| Dec 31, 2023 | -667.56% |
| Sep 30, 2023 | 244.84% |
| Jun 30, 2023 | 192.08% |
| Mar 31, 2023 | 63.93% |
| Dec 31, 2022 | 72.66% |
| Sep 30, 2022 | 50.51% |
| Jun 30, 2022 | 44.70% |
| Mar 31, 2022 | -38.19% |
| Dec 31, 2021 | -109.23% |
| Sep 30, 2021 | -1,083.02% |